Long-term survival of an infant with an atypical teratoid/rhabdoid tumor following subtotal resection and low-cumulative dose chemotherapy: a case report

Abstract

This case report highlights that independent prognostic factors are urgently needed for optimizing treatment stratification and preventing overtreatment.

Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors

“…In vitro studies have elucidated a multitude of affected pathways and mechanisms as a consequence of SMARCB1 loss in RT, unveiling new potential therapeutic targets. This includes among others the overexpression of Aurora Kinase A, 31,32 upregulation of EZH2, 33 as well as CDK4/CDK6/cyclin D1/RB pathway activation 34,35 and many more. 36 Translation of these findings into clinical trials has been challeng- reported single cases of responses to metronomic chemotherapy regimens in ATRT using either vinorelbine, cyclophosphamide, and celecoxib or in the latter bevacizumab, liposomal cytarabine, celecoxib, cyclophosphamide, and etoposide.…”

“…In vitro studies have elucidated a multitude of affected pathways and mechanisms as a consequence of SMARCB1 loss in RT, unveiling new potential therapeutic targets. This includes among others the overexpression of Aurora Kinase A , 31,32 upregulation of EZH2, 33 as well as CDK4/CDK6/cyclin D1/RB pathway activation 34,35 and many more 36 …”